{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:55:14Z","timestamp":1788897314444,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2001,12,21]],"date-time":"2001-12-21T00:00:00Z","timestamp":1008892800000},"content-version":"vor","delay-in-days":155,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2001,7,19]]},"abstract":"<jats:p> <jats:bold>Abstract<\/jats:bold> <\/jats:p><jats:p> <jats:italic>Aims:<\/jats:italic> To determine whether various markers of bone turnover and\/or plasma cytokines differ in patients with multiple myeloma (MM) compared with patients with monoclonal gammopathies of undetermined significance (MGUS).<\/jats:p><jats:p> <jats:italic>Methods:<\/jats:italic> We studied 22 MM patients and 18 MGUS patients presenting over an 18\u2010month period and compared their data with those from 20 age\u2010 and sex\u2010matched patients presenting with primary osteoporosis. According to the Salmon and Durie classification, there were eight patients with stage I, nine with stage II and five with stage III disease. All patients had densitometric evidence of osteoporosis and were classified according to bone marrow evidence of plasma cell dyscrasia. Measured variables included markers of bone formation and bone resorption, and plasma cytokines.<\/jats:p><jats:p> <jats:italic>Results:<\/jats:italic> Patients with MM and MGUS did not differ with respect to their mean age, male : female sex ratio, height, weight, serum calcium, 25\u2010hydroxyvitamin D and parathyroid hormone concentrations. Patients with MM had significantly lower concentrations of haemoglobin (109 <jats:italic>vs<\/jats:italic> 135 g\/L) and serum transforming growth factor (TGF)\u2010\u03b2 (261 <jats:italic>vs<\/jats:italic> 348 pg\/mL) than patients with MGUS, and higher concentrations of serum paraproteins (31.1 <jats:italic>vs<\/jats:italic> 7.4 g\/L), \u03b22\u2010microglobulin (3.5 <jats:italic>vs<\/jats:italic> 2.2 g\/L), % plasma cell numbers (35.3 <jats:italic>vs<\/jats:italic> 2.1%) and urinary deoxypyridinoline excretion rates (u\u2010DPYD; 7.7 <jats:italic>vs<\/jats:italic> 5.9 nmol\/mmol creatinine; <jats:italic>P<\/jats:italic> &lt; 0.05 for all comparisons). In multivariate analysis, the serum paraprotein (\u03b2 coefficient = \u20130.067; 95% confidence intervals (CI), \u20130.019 to \u20130.005; <jats:italic>P<\/jats:italic> = 0.0012), u\u2010DPYD excretion rates (\u03b2 coefficient = \u20130.012; 95% CI, \u20130.113 to \u20130.02; <jats:italic>P<\/jats:italic> = 0.0058) and serum TGF\u2010\u03b2 concentrations (\u03b2 coefficient = \u20130.002; 95% CI, \u20130.0002 to \u20130.02; <jats:italic>P<\/jats:italic> = 0.02) were the most important variables differentiating between MM and MGUS, after excluding lytic bone lesions, % plasma cell numbers and haemoglobin concentrations.<\/jats:p><jats:p> <jats:italic>Conclusions:<\/jats:italic> The well\u2010established criteria for diagnosing MM include the presence of lytic bone lesions, plasmacytosis, haemoglobin and paraprotein concentrations. The u\u2010DPYD excretion rate, a sensitive non\u2010invasive marker of bone resorption, may help in differentiating between MM and MGUS, as well as serving as a marker of underlying bone disease activity in these patients. (Intern Med J 2001; 31: 272\u2013278)<\/jats:p>","DOI":"10.1046\/j.1445-5994.2001.00055.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T02:15:21Z","timestamp":1047435321000},"page":"272-278","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Non\u2010invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance"],"prefix":"10.1111","volume":"31","author":[{"given":"T.","family":"Diamond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,21]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"29","article-title":"Multiple myeloma: Review of 869 cases.","volume":"50","author":"Kyle RA.","year":"1975","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2000.tb00831.x"},{"key":"e_1_2_5_4_2","first-page":"4","article-title":"Advances in the biology and treatment of myeloma.","volume":"105","author":"Morgan GJ.","year":"1999","journal-title":"Br J Haematol"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762","article-title":"Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: A prospective study of 87 bone biopsies.","volume":"87","author":"Bataille R","year":"1996","journal-title":"Blood"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.01082.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8 <1557::AID-CNCR5>3.0.CO;2-H"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(99)80345-3"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90120-E"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198006123022405"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115305"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.8672495.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(96)06334-6"},{"key":"e_1_2_5_15_2","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood.V90.9.3743","article-title":"Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: Quantification by urinary pyridinium crosslinks of collagen.","volume":"90","author":"Pecherstorfer M","year":"1997","journal-title":"Blood"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","unstructured":"PeestD DeicherH FettWet al.Pyridinium cross\u2010links in multiple myeloma: Correlation with clinical parameters and use for monitoring of intravenous clodronate therapy. A pilot study of the German Myeloma Treatment Group. Eur J Cancer 1996; 32A: 2053\u20137.","DOI":"10.1016\/S0959-8049(96)00228-6"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1997.tb00932.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0009-8981(97)00181-2"},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/clinchem\/43.1.85","article-title":"Bone sialoprotein in serum of patients with malignant bone disease.","volume":"43","author":"Withold W","year":"1997","journal-title":"Clin Chem"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.1042920.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05609.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.19.1.18"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000203682"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609045719"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb03296.x"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02989591"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01651.x"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1445-5994.2001.00055.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1445-5994.2001.00055.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T10:00:52Z","timestamp":1697623252000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1445-5994.2001.00055.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7,19]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,7,19]]}},"alternative-id":["10.1046\/j.1445-5994.2001.00055.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1445-5994.2001.00055.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7,19]]},"assertion":[{"value":"2001-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}